Loading...

CPIX CUMBERLAND PHARMACEUTICALS INC Investments/Divestments 8-K Filing

CMBR

CPX

CUMBERLAND PHARMACEUTICALS INC

(CPIX)

2023 8-K

Show Summary

Summary

Financial Statements

Clinical Trial Update

Financial Results

Product Approval

Stock Offering Increase

FDA Designation Granted

Financial Results

Research Publication

Medicare Reimbursement

Financial Results

Financial Results

Annual Meeting of Shareholders

At-the-Market Offering Program

Financial Results

Financial Results Announcement

Clinical Study Results

Financial Results

Interim Analysis Results fo...

FDA Waiver Granted

Appointment of Accountant

Change in Accounting Firm

FDA Approval for Caldolor L...

Earnings Report

Annual Meeting of Shareholders

Medicare Reimbursement

FDA Waiver Refund

Compensatory Arrangements o...

Financial Results

Departure of Directors

External Links:

Cumberland Pharmaceuticals expects its Caldolor product to be eligible for special Medicare reimbursement under the NOPAIN Act, which will affect Medicare reimbursement for the non-opioid analgesic injection product.

AI Assistant

CUMBERLAND PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.